Medtronic Makes Strategic Investment in Pi-Cardia

September 11, 2026—Medtronic and Pi-Cardia Ltd., a developer of leaflet modification technologies for structural heart disease, announced that Medtronic has made a strategic investment in Pi-Cardia.

Medtronic, which is focused on addressing increasingly complex transcatheter aortic valve replacement (TAVR) patients and procedures, secured an option for strengthening its structural heart portfolio, noted the press release.

Under the agreement, Medtronic will make strategic investments of up to $80 million into Pi-Cardia and is expected to become the exclusive global commercial distributor of the Pi-Cardia’s ShortCut device in 2027. Medtronic will leverage its worldwide Structural Heart organization to expand physician access to the device across the United States, Europe, Japan and other international markets, noted the press release.

Additionally, the companies stated that the agreement includes an option for Medtronic to acquire Pi-Cardia upon achievement of predefined milestones for an estimated upfront acquisition price of up to $210 million, subject to customary adjustments, plus additional potential earn-out payments post acquisition that could meaningfully increase the total consideration. The transactions are subject to regulatory approval and customary closing conditions.

According to the companies, Pi-Cardia’s ShortCut device is an FDA-cleared leaflet modification technology designed to enable valve-in-valve TAVR procedures in patients at risk of coronary obstruction. In FDA-reviewed clinical studies, ShortCut has demonstrated successful leaflet splitting in all pivotal trial patients and a favorable safety profile, reported the companies.